Who Paid My Doc
John Gambol
Undersea and Hyperbaric Medicine Placentia, CA Medical Doctor
NPI 1255339826 CMS profile 11590
1041 E Yorba Linda Blvd Ste 203, Placentia, CA 92870
General payments
$1,208
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, John Gambol of Placentia, CA is reported in the CMS Open Payments database as having received $1,208 across 53 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 71st percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $24 | 1 | |
| 2024 | General | $242 | 3 | |
| 2023 | General | $152 | 6 | |
| 2022 | General | $122 | 5 | |
| 2021 | General | $218 | 10 | |
| 2020 | General | $180 | 10 | |
| 2019 | General | $270 | 18 |
Beside peers
- John Gambol
- Undersea and Hyperbaric Medicine median
- Middle half of Undersea and Hyperbaric Medicine
- National median
In program year 2025, general payments to John Gambol were reported at $24. Among 65 Undersea and Hyperbaric Medicine profiles paid that year, the median was $153 and the middle half received between $68 and $340.
Show as a table
| Year | John Gambol | Undersea and Hyperbaric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $270 | $162 | $85–$376 | $163 |
| 2020 | $180 | $111 | $46–$307 | $114 |
| 2021 | $218 | $154 | $50–$306 | $132 |
| 2022 | $122 | $122 | $40–$378 | $149 |
| 2023 | $152 | $145 | $52–$410 | $160 |
| 2024 | $242 | $146 | $80–$316 | $164 |
| 2025 | $24 | $153 | $68–$340 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
506
Drug cost
$14,177
Branded share of claims
32%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cefpodoxime Proxetil | Generic | 33 | $4,467 | |
| Gentamicin Sulfate | Generic | 69 | $3,489 | |
| Ssd Silver Sulfadiazine | Brand | 107 | $2,667 | |
| Ciprofloxacin Hcl | Generic | 65 | $534 | |
| Doxycycline Hyclate | Generic | 39 | $513 | |
| Silver Sulfadiazine | Generic | 28 | $498 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 29 | $472 | |
| Gabapentin | Generic | 20 | $397 | |
| Fluconazole | Generic | 22 | $397 | |
| Mupirocin | Generic | 28 | $335 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 21 billing codesPaid by Medicare
$193,905
Medicare patients
190
Services billed
3,855
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 69% | |
| Diabetes | 53% | |
| Ischemic heart disease | 39% | |
| Chronic kidney disease | 39% | |
| Heart failure | 37% | |
| Atrial fibrillation | 35% | |
| Osteoporosis | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
53 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Undersea and Hyperbaric Medicine in California
Sandra Hayes
Undersea and Hyperbaric Medicine · Coronado, CA
William Toppen
Undersea and Hyperbaric Medicine · San Diego, CA
John Deacon
Undersea and Hyperbaric Medicine · Santa Barbara, CA
Gary Willard
Undersea and Hyperbaric Medicine · Carlsbad, CA
Kenneth Kelly
Undersea and Hyperbaric Medicine · San Diego, CA
Stephen Lazarus
Undersea and Hyperbaric Medicine · San Clemente, CA
Related records
Undersea and Hyperbaric Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Undersea and Hyperbaric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.